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The bacteriophage P1 Cre//oxP system has become a powerful tool 
for in vivo manipulation ofthe genomes of transgenic mice. Although 
in vitro studies have shown that Cre can catalyze recombination 
between cryptic "pseudo-/oxP" sites in mammalian genomes, to date 
there have been no reports of loxP-site infidelity in transgenic ani­
mals. We produced lines of transgenic mice that use the mouse 
Protamine 1 (Prml) gene promoter to express Cre recombinase in 
postmeiotic spermatids. All male founders and all Cre-bearing male 
descendents of female founders were sterile; females were unaf­
fected. Sperm counts, sperm motility, and sperm morphology were 
normal, as was the mating behavior of the transgenic males and the 
production of two-celled embryos after mating. Mice that expressed 
similar levels of a derivative transgene that carries an inactive Cre 
exhibited normal male fertility. Analyses of embryos from matings 
between sterile Cre-expressing males and wild-type females indi­
cated that Cre-catalyzed chromosome rearrangements in the sper­
matids that lead to abortive pregnancies with 100% penetrance. 
Similar Cre-mediated, but /oxP-independent, genomic alterations 
may also occur in somatic tissues that express Cre, but, because of the 
greater difficulty of assessing deleterious effects of somatic muta­
tions, these may go undetected. This study indicates that, following 
the use of the Cre//oxP site-specific recombination systems in vivo, it 
is prudent to eliminate or inactivate the Cre recombinase gene as 
rapidly as possible.
T he bacteriophage PI recombinase, Cre, is a member of the 
integrase family of site-specific recombinases that catalyzes 
recombination between loxP DNA elements as a part of the 
normal viral life cycle ( l, 2). All members of the integrase family 
share a similar mechanism of action (3). In Cre-mediated 
recombination, individual loxP sites are bound by Cre ho­
modimers (4). Two Cre-bound loxP sites interact in the recom­
bination reaction. The loxP site is a 34-bp element consisting of 
two 13-bp inverted repeats separated by a directional 8-bp core 
(l, 5-7). During cleavage, Cre Tyr324 becomes covalently linked 
to the 3'-phosphate, forming a DNA-phosphotyrosine interme­
diate (8, 9). Interaction with a second to.i'P-bound Cre dimer 
allows nucleophilic attack ofthe 3'-phosphotyrosine in one loxP 
site by the free 5'-hydroxyl of the other. This ligation reaction 
induces a structural rearrangement of the tetrameric complex, 
allowing the same reaction to occur on the second strand of 
each loxP site, thus completing the strand exchange reaction 
(8, 10—12).
Cre has proven to be a valuable tool for manipulating the 
genomes of mammalian cells and of mice in situ (13-19). As an 
example, Cre-mediated recombination has all but eliminated the 
problem of "selection cassette effects” associated with some 
targeted mutations (15). Although Cre is most commonly used 
to generate short deletions in transgenic mice (13), it has also 
proven useful for recombination between sites up to several 
centimorgans apart on individual chromosome arms (17) and for 
catalyzing unequal sister-chromatid exchanges in cultured cells 
and in mice (17, 18).
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In vitro studies have shown that Cre recombinase is capable 
of catalyzing recombination between DNA sequences found 
naturally in yeast (20, 21) and mammalian (22) genomes, 
termed "pseudo-/o.i'P sites.” These illegitimate sites often bear 
little primary sequence similarity to the phage P I loxP element 
(22). Nonetheless, there have been, as yet, no reports of 
Cre-site infidelity in transgenic animals, suggesting that ille­
gitimate Cre recombination might not occur in vivo. The 
apparent fidelity of Cre for bona fide loxP sites in vivo has led 
to numerous proposals and pilot studies that employ the 
Cre//ai'P system in human gene therapy protocols as a means 
for assembling genetic elements in situ (14, 23, 24), for 
targeting foreign elements into the genome (22, 25), or for 
removing unwanted exogenous genetic elements posttherapy 
(26-29). In this study, we show that chronic high-level expres­
sion of Cre in the spermatids of transgenic mice leads to male 
sterility with 100% penetrance. These results indicate that Cre 
can catalyze illegitimate recombination having overt patho­
logical consequences in animals.
Materials and Methods
Design of Expression Vectors and Production of Transgenic Mice. The
mouse protamine I (Prm I )-Cre-human growth hormone 
(hGH) vector (30) contains mouse prml sequences extending 
from 4.1 -kb pairs upstream of the cap site to a synthetic linker 
inserted 91 bp downstream of the cap site (31) fused to a 
version of the bacteriophage PI Cre cistron, which had been 
modified for expression in mammalian cell nuclei (13), fol­
lowed by 0.8 kb of genomic 3' flanking sequences from the 
hGH gene extending from a BglII site near the 3' end of 
protein-coding region of the last exon, through the polyade- 
nylation site and signals, to the 3' EcoRI site (Fig. I a; ref. 32). 
To create the CreYI_VD cassette, Tyr324 and lie325 were con­
verted to Val and Asp, respectively (sequence TAT ATC 
converted to GTC GAC, creating an Sail site) by PCR- 
mediated site-directed mutagenesis. All constructs were con­
firmed by sequencing. CreYI_VD-hGH was inserted into both 
the Prm I transgenic mouse expression vector and a cytomeg­
alovirus (CMV) expression vector (33). In both cases, the 
91 -bp 5'-untranslated region from the prml gene was retained.
Transgene vectors were linearized, DNA was microinjected into 
one pronucleus of fertilized eggs from matings between wild-type 
C57BL/6 mice, and pups were reared in surrogate mothers (34). At 
weaning, tail snips were harvested and DNA was prepared for
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Fig. 1- Postmeiotic chromatin disorganization in Prm1 -Cre-hGH male mice, (a) Transgene structure. Red indicates sequences derived from the mouse Prm1 gene; 
yellow denotes the bacteriophage P1 Cre gene; and blue denotes 3' flanking sequences from the hGH gene, (b) Sperm morphology. High magnification of 
wild-type and Prm1 -Cre-hGH spermatozoa showed no visible differences. The focal plane was set to show the sperm head shape; differences in tail-shaft 
appearance are because of focal plane, (c) DAPI-stained chromosome spreads of fertilized eggs from matings between wild-type females and either wild-type 
(Left) or Prm-Cre-hGH males (Right), (d) Meiotic chromosome spreads from wild-type and Prm1 -Cre-hGH testes. Testicular sperm at various stages of condensation 
appear in meiosis II spread fields for stochastic reasons.
PCR-based genotyping. Transgcnc copy was estimated by quanti­
tative PCR and by Southern blotting (30). Founders bearing the 
transgene were mated with wild-tvpe C57BL/6 mice.
Karyotyping and Embryo Counts. For examining the chromosomal 
spreads of fertilized eggs, wild-tvpe C57BL/6 females were 
mated with wild-tvpe or heterozygous Prml-Cre-hGH trans-






Table 1. In vitro embryo development
Number of embryos at various times after mating
0.5 day 1.5 days 2.5 days 3.5 days
Male (Egg harvest) 1 2 3 4 M 1 2 3 4 M 1 2 3 4 M
wt (66 eggs)* 27 36 3 — — 26 3 14 12 11 26 3 3 2 32
Cre (60 eggs)* 40 19 1 — — 33 16 7 4 — 33 16 7 4
Three wild-type (wt) and three heterozygous Prm1-Cre-hGH (Cre) males were mated with wild-type females (all males were 12-24 wk old, females were 6-8 
wk old), and eggs were harvested from oviducts of sacrificed females on the following morning (0.5 day postmating). Zygotes were cultured for 3 days, and the 
number of 1-, 2-, 3-, 4-, and >4-celled (morulae and blastocysts) embryos (1-4 and M, respectively) were counted each day.
*Someof theone-celled embryos may have been unfertilized eggs or may have been damaged during harvest, accounting for the embryos that did not progress 
beyond the one-celled stage in matings with either wild-type or Prm1-hGH-Cre males. Embryos harvested at 2.5 days after fertilization from matings with either 
wild-type or Prm1-Cre-hGH males contained only 10% one-celled embryos (see text), which is consistent with this interpretation.
genic males, and fertilized eggs were harvested from the oviducts 
the next morning. Cumulus cells were removed from egg clusters 
by using 0.3 mg/ml hyaluronidase in M2 medium (Sigma). Eggs 
were incubated overnight at 37°C in Ml 6 medium (Sigma) 
containing 0.5 /ng/ml colcemid. Zona pelucidae were removed 
by using acidic Tyrode’s solution (Sigma). Eggs were swollen in
0 .1 mM KC1, fixed in methanol/acetic acid (3:1), and metaphase 
chromosome spreads were attached to slides. Slides were stained 
with 4',6-diamidino-2-phenylindole (DAPI) and photographed 
by fluorescence microscopy.
For egg and embryo progression counts, eggs were harvested 
from the matings described in Table I as described above, and 
these were cultured in M l 6 media in a humidified, 5% CO?, 37°C 
incubator.
To examine meiotic chromosomal spreads, cells were 
squeezed from seminiferous tubules of adult wild-type or Prml - 
Cre-hGH mice and swollen in I % sodium citrate solution. After 
fixation (see above), metaphase chromosomes were attached to 
slides, stained with Geimsa solution, and photographed by using 
phase contrast microscopy.
RNase Protection Analyses. RNase protection analyses were per­
formed as described previously (30). The Cre probe, which 
hybridizes to 193 bases of either Cre or CrcYI"VD mRNA, and the 
Prml probe, have been described previously (30). All hybrid­
izations contained the amount of total testis RNA indicated in 
the figure, supplemented with yeast RNA to a total of 50 /xg. For 
Cre analyses, 20 fmol of probe was used in each hybridization; 
for Prm analyses, probe-specific activity was reduced 30-fold, 
and 100 fmol of probe was used.
Recombination Assay. For an in vivo recombination substrate, a
1.25-kb fo.i'P-flanked fragment of arbitrary bacterial sequence 
was inserted into a Bam HI site near the middle of an arbitrarily 
chosen 5.4-kb EcoRI fragment of mouse genomic sequence in a 
Bluescript SKr vector (Stratagene). Primers flanking the 
BamHI site yield a 108-bp PCR product on mouse genomic 
sequence (data not shown), but no product with human genomic 
DNA (Fig. 2d, lanes I and 2). Nonrecombined vector yields a
1.4-kb-pair PCR product, whereas recombination excises the
1.25-kb-pair to.i'P-flanked insert yielding a 180-bp loxP- 
containing PCR product (Fig. 2d, lanes 3-9).
Recombination substrate plasmid, CMV-Cre expression vec­
tor, and Bluescript carrier DNA were mixed as indicated in the 
figure and transfected into human kidney H293 cells with 
Superfect (Qiagen, Chatsworth, CA) using the manufacturer’s 
protocols. After 48 h, cells were rinsed twice with PBS and 
harvested by scraping in 10 mM Tris, pH 7.5, 5 mM EDTA, I % 
SDS, and 200 /ng/ml proteinase K. After incubation at 50°C for
2 h, proteins were removed by phenol/chloroform extraction. 
Samples received 0.5 volumes of 5 M NaCl and two volumes of 
ethanol, and DNA was spooled out for analysis by PCR.
Fig. 2. CreYI VD mutant, (a) Somatic cell CreYI VD-hGH expression vectors. 
Colors as in Fig. 1a; green denotes CMV promoter sequences, (fa) In vivo 
recombination assay. A fragment of arbitrary extragenic mouse genomic 
DNA (light blue) containing two loxP sites (red) flanking a 1.2-kb insert 
(green) was transiently cotransfected into human 293 cells with either 
CMV-Cre-hGH (lanes 4-6) or CMV-CreYI VD-hGH. After 48 h, DNA was 
extracted and analyzed for recombination by using the indicated PCR 
primers. Lane M, DNA size markers. Lanes 1 and 2, Cells transfected with 2.0 
(xg CMV-Cre-hGH or CMV-CreYI VD-hGH, respectively. Lane 3, Cells trans­
fected with 1.0 ng substrate plasmid only. Lanes 4-6, Cells cotransfected 
with 1.0 ng substrate plasmid and 2.0 ng, 0.2 ng, or 0.02 ng of CMV-Cre- 
hGH expression plasmid, respectively. The similar yield of recombined 
product in all three lanes indicates that even the lowest amount of CMV- 
Cre-hGH plasmid yielded 100% recombination in cotransfected cells. Un­
recombined substrate in lanes 4-6 likely stems from substrate plasmid that 
did not enter cells and therefore was not exposed to Cre. Lanes 7-9, Like 
lanes 4-6, except that CMV-CreYI VD-hGH was used in place of CMV-Cre- 
hGH. In all cases, Bluescript plasmid vector DNA was used to supplement 
each transfection to a total of 3.0 ng DNA. (d) Expression of Prm1-Cre-hGH 
and Prm1-CreYI VD-hGH mRNAs in transgenic mouse testes. RNase protec­
tion analyses were performed on the indicated amounts of total RNA 
harvested from testes of 12-to 14-wk-old wild-type (wt), Prm1-Cre-hGH, or 
Prm1-CreYI VD-hGH mice. The Cre probe hybridizes to 193 bases of either Cre 
or CreYI VD mRNA. The endogenous Prml mRNA signal served as a normal­
ization control.
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Production and Phenotype of Prm1-Cre-hGH Mice. Wc wished to 
crcatc a line of transgcn ic micc that expressed Cre in postmciotic 
spermatids to catalyze specific deletions in the germ lines of 
mouse lines bearing /ovP-flanked scqucnccs. Wc inserted a Cre 
rccombinasc transgcnc, which had been modified for activity in 
cukaryotic ccll nuclci (13), between a 4.1 -kb region of the mouse 
prrnl promoter (31) and 3'-flanking scqucnccs from the hGH 
gene (32). This vcctor wasinjcctcd into the pronuclci of fertilized 
C57BL/6 mouse eggs (Fig. I a: ref. 30). Wc obtained five male 
and three female founders bearing the Prrnl-Cre-hGH trans­
gcnc. All five males were viable and robust, but infertile. The 
females were normal and fertile. Curiously, all Cre-bearing male 
descendents of these females, although exhibiting normal health 
and viability, were also infertile. Conversely, male descendents 
lacking the Cre transgcnc and all female descendents exhibited 
normal fertility yielding litters with normal sex ratios. Wc have 
followed the progeny of one of these founders for seven gener­
ations and those of another for three, yet wc have obtained no 
fertile males bearing the transgcnc. None of these animals 
carried exogenous /arP sites. RNase protection analyses con­
firmed that the transgenic males expressed the Cre transgcnc in 
their testes (see below).
Bccausc all female and male founder lines resulted in the same 
male-sterility phenotype, wc conclude that the phenotype arose 
from transgcnc expression and not from the site of transgcnc 
integration into the mouse genome. The same expression cas­
sette has been used to generate micc expressing other transgenes 
in their haploid spermatids, including the jellyfish green fluores­
cent protein (GFP) and hGH (30, 32). These transgenic micc 
generally exhibited normal male fertility, even though they often 
had transgcnc copy and mRNA expression levels exceeding 
those for the Prrn l -Cre-hGH transgcnc in the current study 
(data not shown; ref. 30).
The Prrn l-Cre-hGH males exhibited normal mating behavior 
based on the presence of semen plugs in wild-type female 
partners after overnight matings. Semen harvested from the vas 
deferens of transgenic males showed normal sperm counts. 
Sperm motility was similar to that of wild-type males, and sperm 
exhibited no apparent morphological abnormalities (Fig. 15).
Lethality of Embryos Derived from Matings Between Prm-Cre-hGH 
Males and Wild-Type Females. Wc next harvested 0.5-day zygotes and
2.5-day embryos from the oviducts of wild-type females mated with 
the transgenic males or with wild-type control males (Table I). The
0.5-day zygotes exhibited two visible pronuclci, indicating that eggs 
were successfully bound and fertilized by sperm from both wild-type 
and Prm 1 -Cre-hGH males. Overnight culture of the embryos from 
either transgenic or wild-type males yielded large numbers of 
two-celled embryos, indicating that sperm from the Prrn l-Cre- 
hGH micc were able to activate embryonic development. Unlike for 
embryos from wild-type matings, of which most progressed to the 
four-cell stage or beyond following an additional 48 h in culture, few 
embryos from transgenic male founders progressed to the four-cell 
stage. Embryos harvested at 2.5 days from control males were 
predominantly morulae (85% at 4- to 16-cell stage: 21 embryos 
from 2 mated females), whereas embryos from matings with the 
Prml-Cre-hGH transgenic males were arrested at the I- (10%), 2- 
(86%), 3- (2%>) , or 4-cell (2%) stage (48 embryos from 4 mated 
females).
Studies of transgcnc inheritance indicated that lines from our 
female founders each had a single independent site of transgcnc 
insertion. Bccausc only females were fertile, only heterozygous 
transgenic animals could be generated. Therefore, half of the 
sperm from transgenic males were hemizygous-wild-type. How­
ever, no sperm were capable of contributing to an embryo that 
could develop past the four-cell stage. Wc have previously used
Results highly sensitive techniques to look for spermatid mRNAs in 
epididymal sperm (Prrnl and TATA box-binding protein 
mRNA) and were unable to detect any (ssO. I mRNA molecule 
per spermatozoan; ref. 35), suggesting that mRNAs synthesized 
during spermiogcnesis arc neither packaged into sperm nor 
transported to the egg. Thus, the phenotype is not likely to stem 
from Cre expression postfertilization (see below), but rather, 
from a Crc-dcpendent modification of the sperm that has no 
effect on the quantity, motility, morphology, egg-binding, fer­
tilization, or embryogenic activation potential of the sperm.
Transgene-containing and transgene-lacking sperm from het­
erozygous males appeared to be equally affcctcd. Bccausc the 
vcctor that wc used directs transgcnc expression exclusively in 
postmciotic spermatids (30-32, 36), the Prm I -Cre-hGH transgcnc 
is likely affecting hemizygous-wild-type sperm only after they have 
been segregated from their hemizygous-transgenic sister nuclci by 
meiosis II (see below). Postmciotic sister spermatids arc connected 
by cytoplasmic bridges that allow the transfer of mRNA and/or 
protein (37-39). Wc hypothesize, therefore, that, in heterozygous 
males, a product from hemizygous transgenic spermatids, either 
Cre mRNA or Cre protein, traversed the cytoplasmic bridges and 
compromised the hemizygous-wild-type sperm (see below). Bc­
causc Cre is capable of binding, cleaving, and trans-ligating DNA 
(8,9), a likely mechanism of sterility would involve one or more of 
these activities.
Chromosomal Consequences of Spermatid-Specific Cre Expression. To
examine the transgenic karyotype, transgenic males were mated 
with wild-type females and fertilized eggs were harvested. These 
were incubated overnight in colcemid, at which time chromo­
some spreads were prepared. Colcemid has two effects in this 
assay: it blocks nuclear migration, such that male and female 
pronuclci remain separated, and it arrests nuclci in metaphase. 
As a result, male and female pronuclci can be detected as 
adjacent but discrete entities. Eggs fertilized by wild-type males 
gave two adjacent spreads, having 20 normal chromosomes in 
each. Eggs fertilized by transgenic males gave one apparently 
normal spread of 20 chromosomes and one with "scrambled 
DNA,"" having amorphous regions of chromatin condensation 
connected by fine strands of DNA (Fig. Ic). Bccausc pronuclci 
containing normal haploid spreads never contained a visible Y 
chromosome, wc infer that these were from the female pronu­
clci, and that the scrambled spreads were from the male pro­
nuclci. In every case, only one pronucleus was visibly affcctcd, 
further confirming that the effect did not likely stem from 
expression of transported Cre mRNA or protein in the fertilized 
egg (see above). The quantity of DAPI fluorescence in each 
scrambled male pronucleus indicated that they were haploid, 
which is consistent with the idea that scrambled DNA resulted 
from rearrangements after the completion of meiosis II (see 
above), and subsequent to the segregation of the individual 
haploid nuclci. If scrambling had occurred earlier, wc would 
expect the male pronucleus to contain diploid (if scrambling 
were before meiosis II), tetraploid (if before meiosis I), or 
intermediate (if during S phase) DNA content. To further test 
this hypothesis, wc prepared chromosome spreads from wild- 
type and transgenic mouse testes. Both meiosis I and meiosis II 
chromosomes from transgenic male testes showed no signs of 
scrambling and were indistinguishable from those of the wild- 
type controls (Fig. Id), which confirmed that chromosome 
scrambling followed completion of meiosis II.
Cre Enzyme Activity Is Required for Chromatin Scrambling in the 
Transgenic Mice. Taken together, the results dcscribcd above 
imply strongly that male infertility in the transgenic micc occurs 
in the testis from some postmciotic action of a Cre transgcnc 
product, expressed independently of the transgene’s insertion 
site, and transmitted through cytoplasmic bridges to wild-type






male spermatids. However, the results did not determine 
whether the chromatin scrambling resulted from Cre-mediated 
enzymatic activity. Therefore, we produced a second transgene 
that was identical to the first in all respects except that Tyr324 and 
lie325 of Cre were converted to Val and Asp, respectively 
(CreYI‘VD mutant). This mutation was chosen for four reasons: 
First, Tyr324 forms the covalent DNA-phosphotyrosine interme­
diate in Cre catalysis (see above) and Val cannot participate in 
this reaction. Second, these amino acids are near the C terminus 
of the 343-residue protein and are away from the hydrophobic 
core (9), reducing the likelihood that they would disrupt overall 
protein structure. Third, neither of the mutated amino acids is 
among the 42 nonactive-site amino acids in Cre that contact 
DNA (<3.6 angstroms; ref. 9), reducing the likelihood that the 
mutations would affect DNA-binding or Cre-Cre interactions. 
Finally, by using this substitution, we could introduce a diag­
nostic restriction enzyme recognition site into the mutant while 
making a replacement that was not expected to disrupt the local 
a-helical nature of this region of the protein.
To test the effectiveness of this mutation, both wild-type Cre 
and 0<rYI'VD were cloned into a CMV promoter-based expres­
sion vector (33), and these were transiently cotransfected into 
human 293 cells with a /arP-containing recombination substrate 
(Fig. 2 a and b). Analyses after 48 h revealed efficient recom­
bination of the substrate by wild-type Cre, but no detectable 
recombination by Cre YI‘VD (Fig. 2c).
Next, transgenic mice bearing the Prml-CreYI‘VD-hGH trans­
gene were produced. Males bearing the mutant transgene were 
found to exhibit normal fertility. RNase protection analyses were 
used to compare transgene mRNA expression in testes from a 
sterile Prml-Cre-hGH transgenic mouse line and a fertile Prml- 
CrCYi-vD-hGH mouse line (Fig. 2d). The results showed that 
transgene mRNA expression was similar between the two lines. We 
conclude that it is the Cre recombinase activity that induces male 
sterility in the Prml-Cre-hGH mice. Specifically, the subtle nature 
of the rescuing mutation in Prml-CreYI‘VD-hGH, affecting only the 
active-site DNA-cleavage residues of Cre, leads us to posit that 
infertility in the Prml-Cre-hGH males stemmed from hydrolysis 
and/or ligation of DNA mediated by Cre recombinase.
Discussion
The Cre//arP site-directed recombination system has become an 
important tool for genetic manipulation of transgenic animals 
and may have future importance as a tool for human gene 
therapy. In the current study, we show that persistent high-level 
Cre expression in the spermatids of transgenic mice can lead to 
gross chromosomal rearrangements in spermatozoa. The rear­
rangements are dependent on Cre enzyme activity, but occur in 
the absence of exogenous loxP sites. Our finding may have 
important implications for in vivo use of the Cre/foxP system. 
Specifically, they emphasize the importance of limiting the 
duration of in vivo Cre expression to only the period required for 
the desired recombination event, rather than allowing chronic 
Cre activity in the target cells.
Many lines of transgenic mice that express the Cre recombinase 
gene have been generated in multiple laboratories. However, this is 
the first report of an overt effect of Cre in mice that is independent 
of exogenous (i.e., transgenic) loxP sites. Thus, we may ask why 
similar effects have not been reported previously. Several factors 
may have contributed to the outcome of our experiments. First, a 
very proficient promoter was used to direct the expression of the Cre 
transgene, which might increase otherwise undetectable rates of 
Cre-mediated recombination between pseudo-/arP sites. Second, 
the target tissue for Cre expression was developing spermatids, 
which may have influenced the outcome in several ways. Thus, only 
mutations that affect the germ line, as opposed to the somatic 
genome, are transmitted from generation to generation, which 
makes them readily apparent. In addition, the spermatid genome
undergoes dramatic chromatin reorganization wherein histones are 
replaced by transition proteins and protamines (40). During this 
transition, the DNA of spermatids may be particularly vulnerable to 
Cre-mediated reactions.
Conversely, if the expression of the Cre transgene is restricted 
to somatic tissues, the consequences of recombination between 
pseudo-/arP sites in these cells could be missed. If the cells were 
dividing, a likely consequence of such genomic alterations would 
be cell death because of the inability to properly segregate 
chromosomes between daughter cells. Only if the fraction of 
dying cells in the Cre-expressing tissue were very large would 
there be a likelihood of detecting an associated defect in the 
affected tissue. Mammals are remarkably tolerant of the effects 
of somatic cell death. For example, during normal development, 
approximately half of the neurons generated by both the central 
and peripheral nervous systems undergo programmed cell death 
(41). Other tissues can exhibit similarly high levels of pro­
grammed cell death as well (42).
Interestingly, a previous study reported the generation of mice 
carrying a Cre transgene driven by a promoter similar to that 
reported here (43). However, those transgenic mice were not 
reported to exhibit male sterility. Because both the current and 
former studies produced multiple independent founder lines, the 
difference in phenotypes is likely because of differences in Cre 
expression rather than to effects of different transgene insertion 
sites. The previous study used a truncated form of the Prml 
promoter (i.e., 652 bp as compared with 4100 bp in our vector), used 
a different untranslated region, which is known to affect the timing 
of translation of spermatid mRNAs (30, 32), and incorporated an 
epitope tag. These differences are likely to have resulted in lower 
levels of Cre transcription, as well as differences in the timing of Cre 
mRNA translation or accumulation of Cre protein within the nuclei 
of developing spermatids. Any of these effects could readily ac­
count for the differences in phenotype exhibited in the two studies.
It is possible that Cre-mediated recombination reactions 
similar to those described here in developing spermatids can also 
occur in somatic cells. However, as discussed above, the fre­
quency of such events may be lower in somatic tissues. The RAG 
recombinases of vertebrate immune systems are also members of 
the integrase family, and, like Cre, show high target site fidelity 
(3). Nevertheless, translocations caused by rare instances of site 
infidelity by RAG recombinases in somatic cells are involved in 
many human leukemias (44, 45).
In summary, we have demonstrated that expression of the Cre 
recombinase gene in developing spermatids can lead to male 
sterility with 100% penetrance. The cause of sterility is likely 
because of Cre-mediated genomic rearrangements, perhaps at 
pseudo-/arP sites within the mouse genome. Such sites have been 
identified previously within the mouse and human genomes and 
have been shown to function in Cre-mediated recombination assays 
performed in bacteria and cultured mammalian cells (22). Our 
results suggest that, subsequent to in vivo use of the Ctc/laxP system 
to mediate genomic rearrangements, or to control gene activities in 
a conditional manner, it would be prudent to remove or inactivate 
the Cre gene as rapidly as possible. For such purposes, the self- 
excising Cre vectors described by Bunting et al. (19) may be 
particularly attractive. The potential consequences of Cre-mediated 
recombination between cryptic sites within the human genome 
should also be seriously considered before implementing Cre/foxP- 
based technologies in human gene therapy protocols.
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